CCNE1 AMPLIFICATION
Clinical trials for CCNE1 AMPLIFICATION explained in plain language.
Never miss a new study
Get alerted when new CCNE1 AMPLIFICATION trials appear
Sign up with your email to follow new studies for CCNE1 AMPLIFICATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill takes aim at Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…
Matched conditions: CCNE1 AMPLIFICATION
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New pill aims to shrink tumors in advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests a new daily pill, INX-315, in 150 people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study includes three parts: testing the…
Matched conditions: CCNE1 AMPLIFICATION
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New pill shows promise against Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…
Matched conditions: CCNE1 AMPLIFICATION
Phase: PHASE1, PHASE2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC